Clinical Trial Update: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab [Phase 2]

View source ↗

Summary

This Phase II randomized trial assessed cetuximab with sorafenib versus cetuximab alone in metastatic head and neck squamous cell carcinomas, including occult p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Cancer
• Oral Cavity Cancer
• Paranasal Sinus and Nasal Cavity Cancer
• Salivary Gland Cancer
• Tongue Cancer
• Verrucous Carcinoma of the Larynx
• Verrucous Carcinoma of the Oral Cavity

Drugs mentioned

• Cetuximab (cetuximab)
• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Status: COMPLETED | Results posted: 2015-09-01